Clinuvel Pharmaceuticals Limite

CUVL

Last

$5.58

Day

+0.4%

—

52w

—

SPY YTD

+13.3%

XLV

+8.1%

Earnings

—

EMA 21

—

EMA 50

—

EMA 200

—

20d high

—

5y high

—

5y range

—

Website · Australia

Positions held

Your positions

CUVL isn't in your positions.

Add it to see shares, cost, and P&L here.

Score

—

Hold

—

Signal

—

Target

—

Stop

—

Stop distance

—

Target vs last

—

Fundamentals

Market cap	$282.73M	Enterprise value	$32.28M	Trailing P/E	12.44	Forward P/E	—
PEG	—	Price / book	1.49	Beta	0.58	Dividend yield	0.64%
Revenue growth	-3.8%	Earnings growth	5.3%	Gross margin	83.2%	Operating margin	47.3%
Profit margin	36.1%	ROE	13.2%	ROA	8.9%	Debt / equity	0.01
Current ratio	14.81	Free cash flow	$25.39M	Analyst recommendation	none	Mean target	—
52w high	$8.92	52w low	$5.53

Quarterly

No data yet.

Yearly (6y)

	2026	2025	2024	2023	2022
Revenue	$94.0M	$95.0M	$88.2M	$78.3M	—
Op margin	42.1%	48.1%	54.4%	56.3%	—
Net income	$33.9M	$36.2M	$35.6M	$30.6M	—
Gross margin	83.2%	83.3%	88.6%	88.8%	—
Gross profit	$78.2M	$79.1M	$78.1M	$69.5M	—
Operating income	$39.5M	$45.7M	$48.0M	$44.1M	—

Headline scan

No flags

• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).

News

2026-10-02 · 3 Great Australian Biotech Stocks With P E Under 14

2026-08-27 · A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

2026-07-23 · CLINUVEL implements strategic reorganisation to refocus on U.S. markets

Price (daily)

Full chart · RSI · MACD · patterns

No price history yet for CUVL.